国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (5): 393-396.doi: 10.3760/cma.j.issn.1673422X.2017.05.018

• 综述 • 上一篇    下一篇

VEGF和VEGFR通路抑制剂在晚期胃癌治疗中的疗效

李毛吉,姜雷,关泉林   

  1. 730000 兰州大学第一医院肿瘤内科（李毛吉），肿瘤外科（姜雷、关泉林）
  • 出版日期:2017-05-08 发布日期:2017-04-19
  • 通讯作者: 关泉林，Email： guanquanlin@163.com E-mail:guanquanlin@163.com
  • 基金资助:

    甘肃省科技支撑项目（1504FKCA084）；甘肃省卫生行业科研计划（GSWST2013-16）

Efficacy of VEGF and VEGFR pathway inhibitors in the treatment of advanced gastric cancer

Li Maoji, Jiang Lei, Guan Quanlin   

  1. Department of Medical Oncology, First Hospital of Lanzhou University, Lanzhou 730000, China
  • Online:2017-05-08 Published:2017-04-19
  • Contact: Guan Quanlin E-mail:guanquanlin@163.com
  • Supported by:

    Science and Technology Support Project of Gansu Province of China（1504FKCA084）; Health Industry Science Foundation of Gansu Province of China（GSWST2013-16）

PDF

1128

摘要： 抗新生血管形成是目前胃癌治疗的重要研究方向，血管内皮生长因子（VEGF）及血管内皮生长因子受体（VEGFR）抑制剂是主要的研究热点。目前治疗晚期胃癌的VEGF及VEGFR通路抑制剂包括贝伐珠单抗、雷莫芦单抗、阿帕替尼、瑞戈非尼、索拉非尼等，这些药物为晚期胃癌的治疗提供了更多可能性。

关键词: 血管内皮生长因子类, 受体, 血管内皮生长因子, 胃肿瘤

Abstract: |Antineovascularization is an important research direction in the current treatment of gastric cancer. The inhibitors of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) are main research focus. At present, the inhibitors of the pathways of VEGF and VEGFR in the treatment of advanced gastric cancer include bevacizumab, ramucirumab, apatinib, regorafenib, sorafenib, et al. These drugs provide more possibilities for the treatment of advanced gastric cancer.

Key words: Vascular endothelial growth factors, Receptors, vascular endothelial growth factor, Stomach neoplasms